EUVIMEDOpdag EUVIMED
Crossref

Leveraging genetic predictors of factor XI levels to anticipate results from clinical trials

Iyas Daghlas iD, Dipender Gill

European Journal of Neurology · 2023

DOI: 10.1111/ene.15820 ↗

At a glance

Journal article in European Journal of Neurology, 2023. Written by Iyas Daghlas and 1 co-authors. Institution: Department of Neurology, University of California San Francisco, San Francisco, California, USA. Major MEDLINE topics: Venous Thromboembolism, Thrombosis, Ischemic Stroke. Cited 14 times so far (Crossref); 15 references.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Background

Factor XI (FXI) is a promising therapeutic target for the prevention of thrombotic disease without increasing bleeding risk.

Methods

We performed Mendelian randomization (MR) analyses to investigate the association of genetically predicted reductions in FXI levels with risk of venous thromboembolism, ischemic stroke, bleeding outcomes, and lifespan.

Results

Genetically predicted reductions in FXI levels were associated with lower risk of ischemic stroke (odds ratio per 1 standard deviation (SD) lower serum FXI 0.90, 95% confidence interval 0.87–0.93, p = 1.59 × 10 −11 ), and venous thromboembolism (0.54, 0.49–0.59, p = 2.13 × 10 −39 ) but did not associate with increased bleeding risk ( p > 0.16). Genetically predicted reductions in serum FXI levels associated with longer lifespan (0.37 years per 1 SD lower serum FXI, 0.13–0.61, p = 0.003).

Conclusions

These genetic data support FXI as a potentially efficacious and safe therapeutic target and anticipate positive results from ongoing phase 3 clinical trials.

Subjects

MeSH terms (MEDLINE)

Venous ThromboembolismThrombosisIschemic StrokeHumansFactor XIHemorrhage

Author keywords

FXIMendelian randomizationfactor XIstrokevenous thromboembolism

Substances

Factor XI

Authors and institutions

  • Department of Neurology, University of California San Francisco, San Francisco, California, USA.
  • Department of Epidemiology and Biostatistics, School of Public Health, Imperial College London, London, UK.

ORCID profiles: Iyas Daghlas

Cite

APA

Daghlas, I., & Gill, D. (2023). Leveraging genetic predictors of factor XI levels to anticipate results from clinical trials. European Journal of Neurology. https://doi.org/10.1111/ene.15820

Vancouver

Daghlas I, Gill D. Leveraging genetic predictors of factor XI levels to anticipate results from clinical trials. European Journal of Neurology. 2023. doi:10.1111/ene.15820

BibTeX
@article{Daghlas2023,
  author = {Daghlas, Iyas and Gill, Dipender},
  title = {Leveraging genetic predictors of factor XI levels to anticipate results from clinical trials},
  journal = {European Journal of Neurology},
  year = {2023},
  doi = {10.1111/ene.15820}
}
Start for free →